| 1.535 0.055 (3.72%) | 10-14 12:56 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.61  |
1-year : | 3.19 |
| Resists | First : | 2.24 |
Second : | 2.73 |
| Pivot price | 1.83 |
|||
| Supports | First : | 1.44 | Second : | 1.19 |
| MAs | MA(5) : | 1.5 | MA(20) : | 1.97 |
| MA(100) : | 2.61 |
MA(250) : | 3.72 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 6.5 |
D(3) : | 5.5 |
| RSI | RSI(14): 22.3 |
|||
| 52-week | High : | 9.5 | Low : | 1.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AVXL ] has closed above bottom band by 28.5%. Bollinger Bands are 87.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.53 - 1.54 | 1.54 - 1.55 |
| Low: | 1.45 - 1.46 | 1.46 - 1.47 |
| Close: | 1.47 - 1.48 | 1.48 - 1.49 |
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
Wed, 14 Oct 2026
AVXL Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ... - Black Hills Pioneer
Tue, 13 Oct 2026
Deadline Alert: Anavex Life Sciences Corp. (AVXL) - GlobeNewswire
Mon, 12 Oct 2026
Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar
Sun, 11 Oct 2026
AVXL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Thu, 08 Oct 2026
Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Thu, 08 Oct 2026
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 30, 2026 in Anavex Life Sciences Corp. Lawsuit - AVXL - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 93 (M) |
| Shares Float | 90 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 40.4 (%) |
| Shares Short | 13,570 (K) |
| Shares Short P.Month | 13,900 (K) |
| EPS | -0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -9.7 % |
| Return on Equity (ttm) | -12.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -10.93 |
| PEG Ratio | 0 |
| Price to Book value | 1.26 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|